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Tidball: Thinking PINK

Thinking
PINK
Researcher turns to biochemistry to
improve breast cancer survival rates

Anna Zolkiewska

F

or Kansas State University biochemist Anna
Zolkiewska, the battle against breast cancer starts
in the laboratory.
By studying breast cancer stem cells, Zolkiewska is
working to prevent cancer recurrence and metastasis —
the major causes of death among breast cancer patients.
Around 40,000 U.S. women die from breast cancer every
year, according to the American Cancer Society.
Zolkiewska, associate professor of biochemistry
and molecular biophysics, is using a four-year $1.245
million grant from the National Cancer Institute —
at the National Institutes of Health — to study a
promising breast cancer marker called ADAM12 and
its role in breast tumor-initiating cells, or BTICs. Her
research also has received support from the university’s
Johnson Cancer Research Center, which is a team of
multidisciplinary faculty scientists who perform basic
cancer research.
Breast tumor-initiating cells — known as cancer
stem cells — drive breast tumor progression and tumor
recurrence or metastasis. Zolkiewska’s research can
provide clinicians with better diagnostic tools, new cancer
prevention strategies and improved treatment options.
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“Our studies strive to produce new research and
diagnostic tools for detection of breast tumor-initiating
cells and to develop new therapies to target these cells,”
Zolkiewska said.
While current treatments for breast cancer — such
as surgery, chemotherapy and radiation therapy — can
destroy the majority of tumor cells, these treatments cannot
eradicate cancer stem cells. Current treatments also have
many negative side effects.
“The problem is that cancer stem cells are present
in very low amounts,” Zolkiewska said. “They are
difficult to detect. But we know that they exist and they
are practically resistant to chemotherapy and radiation
therapy.”
Even when chemotherapy appears to work, breast
tumor-initiating cells can cause tumors to re-emerge or
metastasize to bones, lungs or the brain.
“Once metastasis occurs, the chances to cure the
patient decrease dramatically,” Zolkiewska said. “It is
absolutely critical to be able to identify cancer stem
cells and to find more effective treatments against
them.”
Zolkiewska is focusing on ADAM12, which is a
member of the ADAM family of cell-surface disintegrinmetalloproteases. Unlike other current cancer markers
— which are found in both healthy and cancerous
tissues — ADAM 12 is not expressed in healthy human
mammary glands.
Zolkiewska’s work suggests that ADAM12 is induced
precisely in breast cancer stem cells. ADAM12 can be
used with existing markers for improved detection,
isolation and characterization of breast tumor-initiating
cells in the laboratory.
Long term, Zolkiewska wants to understand
exactly how ADAM12 functions in cancer stem cells
at the molecular level. She also wants to know how
breast tumor-initiating cells differ from other breast
tumor cells.
“We might be able to use ADAM12 to develop
targeted therapies to eradicate cancer stem cells with
fewer side effects, which is of great importance,”
Zolkiewska said. “Ultimately, we hope we can improve
the quality of life for breast cancer patients.”

Hui Li and Sara Duhachek Muggy

Zolkiewska also is completing a three-year $444,000
grant from the National Institutes of Health for research
on mutations in the ADAM12 gene. Her research team
includes Hui Li, postdoctoral researcher; Sara Duhachek
Muggy, doctoral student in biochemistry; and Yue Qi,
doctoral student in biochemistry.
By Jennifer Tidball, Communications and Marketing
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